Bristol Myers cited by FDA for misleading claims on Krazati website

Bristol Myers Squibb (NYSE:BMY) has received an "untitled letter" from the U.S. FDA Office of Prescription Drug Promotion over alleged misleading claims being made on a physician website for its cancer drug Krazati (adagrasib).